January 2017

10 January 2017

Applications are invited for M.Pharm/M.Tech / M.Sc / as Senior Research Fellow at Indian Institute of Technology

The history of the IIT system dates back to 1946 when a committee was set up by Hon'ble Sir Jogendra Singh, Member of the Viceroy's Executive Council, Department of Education, Health and Agriculture to consider the setting up of Higher Technical Institutions for post war industrial development in India. The 22 member committee headed by Sri N.R.Sarkar, in its report, recommended the establishment of four Higher Technical Institutions in the Eastern, Western, Northern and Southern regions, possibly on the lines of the Massachusetts Institute of Technology, USA, with a number of secondary institutions affiliated to it. The report also urged the speedy establishment of all the four institutions with the ones in the East and the West to be started immediately. The committee also felt that such institutes would not only produce undergraduates but they should be engaged in research, producing research workers and technical teachers as well. The standard of the graduates should be at par with those from first class institutions abroad.

Applications are invited on plain paper for the following assignment on a purely time bound Project undertaken in the various Departments / Centres / Schools of the Institute.

Interested eligible persons may apply (quote SRIC Reference on the top of the Application) on plain paper giving full bio-data along with attested copies of testimonials and a demand draft of the application fee drawn in favour of IIT Kharagpur payable at Kharagpur on or before last date mentioned against each.

Post : Senior Research Fellow - 01 Post

10 January 2017

Career for M.Pharm, B.Pharm as Senior Project Associate in Indegene

Indegene's scientific and competitive intelligence services lend actionable insights to clients to support their strategic decision making. We provide scientific, clinical, and competitive insights to help align the business development, licensing, clinical development, and marketing activities of our clients to current and future market needs.

Post: Senior Project Associate

10 January 2017

Wellcome Trust/DBT India Alliance invites applications for Senior and Intermediate Fellowship

The Wellcome Trust/DBT India Alliance invites applications for its Senior and Intermediate Fellowship scheme. These Fellowships are available across the full spectrum of biomedical research from fundamental molecular and cellular studies through clinical and public health research*. Interdisciplinary projects are welcome.

10 January 2017

Job in QA, QC, Micro & Production at Rajasthan Antibiotics Ltd | 20 Openings

RAL(Rajasthan Antibiotics Ltd) is a fast track integrated pharmaceutical company, which has commenced its production in 1991 and has grown in size and stature to become one of the country's largest producer of the Sterile APIs.

10 January 2017

Job for Virologist/ Immunologist in World Health Organization

WHO is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends.

Post : Virologist/ Immunologist

10 January 2017

Opening for Marketing Manager in ThermoFisher Scientific

We’re a global biotechnology company dedicated to improving the human condition. Our industry-leading brands are found in nearly every life sciences lab in the world, including innovative instrument systems under the Applied Biosystems and Ion Torrent names. We’re also responsible for a broad range of reagents with our Invitrogen, GIBCO, Ambion, Molecular Probes and Taqman products. With approximately 3,900 patents and exclusive licenses, we’re home to one of the largest intellectual property estates in the life sciences industry

Post: Marketing Manager – Pharma/Biopharma

10 January 2017

Concordia International looking for Assistant Manager - Batch Compliance

Concordia International is the result of the acquisition by Concordia Healthcare Corp (now Concordia International Corp) of the AMCo group on 21 October 2015.The combined businesses are highly complementary to each other, with well established product portfolios, and provide a strong platform for future growth through acquisitions in line with its strategy to build a truly global pharmaceutical company.

Post : Assistant Manager - Batch Compliance

10 January 2017

TURMERIC AS MEDICINAL PLANT FOR THE TREATMENT OF ACNE VULGARIS

{ DOWNLOAD AS PDF }

ABOUT AUHTORS
Priyanka R. Waghmare¹*, Priynka G. Kakade¹ , Prashant L. Takdhat², Ashwini M. Nagrale², SM Thakare², MM Parate³
¹ Dr. R. G. Bhoyar Institute of Pharmaceutical Education and Research,
Wardha, Maharashtra, India
² Dr. R. G. Bhoyar Institute of Pharmacy,
Wardha, Maharashtra, India
³ Daga Memorial Hospital,
Maharashtra, Nagpur, India
*waghmarepriyancka@gmail.com

ABSTRACT
Herbal medicines are gaining increased popularity due to their advantages, such as better patient tolerance, long history of use, fewer side-effects and being relatively less expensive. Furthermore, they have provided good evidence for the treatment of a wide variety of difficult to cure diseases. The skin is the outermost layer of the body that is often easily damaged by environmental factors as well as stress and poor eating habits. Acne vulgaris (or simply acne) is an infectious disease and one of the most prevalent human diseases. Acne is a cutaneous pleomorphic disorder of the pilosebaceous unit involving abnormalities in sebum production and is characterized by both inflammatory and noninflammatory lesions. Common therapies that are used for the treatment of acne include topical, systemic, hormonal, herbal and combination therapy. Although here is a wide market for cosmetic products that offers to improve skin problems, nature also provides a solution to these. Although the medical and surgical treatment options are the same, it is these features that should be kept in mind when designing a treatment regimen for acne. Natural treatments for skin that give lasting results are often better than expensive commercial products and cosmetic procedures. One such natural treatment is turmeric powder for skin. Turmeric is considered safe in amounts found in foods and when taken orally and topically in medicinal quantities. Turmeric’s primary biologically active component is curcumin. Research has shown that curcumin has potent antioxidant, wound-healing, and anti-inflammatory properties, which may prove to be therapeutic against acne. This review focuses on the treatment of acne using turmeric as medicinal drug.

DUBLIN a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, announced its financial guidance for the year ended December 31, 2017. For the full year 2017 revenue will be in the range of USD 1,700 - USD 1,750 million, representing growth of 2 - 5% and earnings per share will be in the range of USD 5.00 - USD 5.20, representing growth of 6 - 11%.

CEO Ciaran Murray commented “We expect 2017 to be another year of revenue and earnings growth for ICON. Our success in developing new customer relationships has further diversified our customer base and we expect to grow revenue by 2 - 5% while reducing the full year concentration of our largest customer to circa 15 - 17%. We continue to see good demand across all of our service lines from large pharma customers alongside a continuing flow of business from mid-size, speciality pharma and device companies. In addition to this organic growth we will continue to deploy capital to maximize shareholder value through a combination of “bolt-on” M&A that will enhance our capabilities and share repurchases.”

The full year 2017 financial guidance assumes:

Top customer concentration to reduce to circa 15 - 17% of revenue from circa 24 - 26% in 2016.
US dollar to Euro exchange rate of USD 1.05 (constant currency revenue growth of circa 3 - 6%).
An effective tax rate of circa 14%.
Circa USD 300 million of free cash flow and capital expenditures of circa USD 45 million.
USD 110 million worth of shares repurchased in Q4 2016 from current USD 400 million repurchase programme contributing circa 10c to 2017 earnings.
Remaining authorisation of USD 290 million to be executed opportunistically during 2017 depending on cash commitments to support M&A pipeline, no additional earnings benefit included in guidance.

With respect to 2016, the company confirmed its current guidance, of earnings in the range of USD 4.60 - USD 4.80 and revenue in the range of USD 1,665 - USD 1,680 million

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3

Read more about Takeda to Acquire ARIAD Pharmaceuticals, Inc

Takeda Pharmaceutical Company Limited announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion. The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017, subject to required regulatory approvals and other customary closing conditions. Sarissa Capital, the holder of 6.6% of ARIAD’s common shares, as well as each of the members of ARIAD’s Board of Directors have agreed to tender their shares to Takeda pursuant to the offer